Skip to main content
. 2016 Dec 27;8(3):5371–5381. doi: 10.18632/oncotarget.14260

Scheme 1. Illustration depicting speculated mode of actions of combination of Gardi-PLGA and DMXAA.

Scheme 1

Gardiquimod encapsulating PLGA nanoparticles in combination with DMXAA is speculated to cause activation of dendritic cells which facilitates immune cell mediated killing of cancer cells. Vasculature disrupting agent DMXAA further aids in inhibition of tumor growth.